What changed
$PFE — AVOID 📊 | 6 MONTHS THESIS
🎯 Q1 2026 | Rev $14.5B | EPS $0.75 vs $0.72 🟢
💡 Consensus expected $0.72 EPS; beat was 4% but the market has not re-rated higher. Historical PE is at median, and the return model projects -2.0% base downside, indicating the beat was already priced in or overshadowed by negative outlook. The gap is that the beat did not change the fundamental trajectory.
📉 Reward/risk: 0.2:1
🏢 Business Quality: 5/10 - Pfizer is a mature pharma company with diversified revenues but facing patent cliffs, COVID product decline, and moderate pipeline risk. Average quality.
📊 Valuation: fair - Current PE 19.6x at 50th percentile of own range; EV/EBITDA likely in line with peers; FCF yield modest.
🔮 Catalyst: Recent earnings report (March 2026) already passed; no new catalyst on horizon
📊 Our read: AVOID. Full analysis →
https://stockduty.xyz/s/PFE0624